efzofitimod

Phase 3Small molecule

AaTyr Pharma, Inc.

efzofitimod is one of 93 small molecule programs targeting Pulmonary Sarcoidosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary SarcoidosisActive, not recruiting

PneumoniaActive, not recruiting

Interstitial Lung DiseaseActive, not recruiting

Pulmonary SarcoidosisPhase 3

Active, not recruiting

PneumoniaPhase 2

Active, not recruiting

Interstitial Lung DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

efzofitimod

AaTyr Pharma, Inc.

Phase 3

1 2

Primaxin

Pfizer

Preclinical

2 3

Acanya

Pfizer

Preclinical

1 4

Retrovir

BBp Consulting, Inc

Preclinical

2 5

Gantanol

CConrado Roberto Hoffmann Filho

Preclinical

2 6

Pepcid

KKenvue Brands

Preclinical

1 7

Aciphex

Akero Therapeutics

Preclinical

1 8

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 9

Alka-Seltzer

AAbbott

Preclinical

1 10

Tylenol

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pulmonary Sarcoidosis1 trial

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Active, not recruiting·AaTyr Pharma, Inc.·Phase 3·NCT05415137·268 enrolled

Pneumonia1 trial

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

Completed·AaTyr Pharma, Inc.·Phase 2·NCT04412668·36 enrolled

Interstitial Lung Disease1 trial

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Recruiting·AaTyr Pharma, Inc.·Phase 2·NCT05892614·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for efzofitimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — efzofitimod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for efzofitimod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — aTyr Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AaTyr Pharma, Inc.

efzofitimod

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pulmonary Sarcoidosis1 trial

Pneumonia1 trial

Interstitial Lung Disease1 trial

References

Drug Info

Quick Facts

Related News